Current guidelines for management of patients with clinical CHD (“secondary prevention”)
| Treatment thresholds | Treatment targets | ||||||
|---|---|---|---|---|---|---|---|
| Guidelines | Cholesterol(mmol/l) | LDL-C (mmol/l) | Chol:HDL-C ratio | Cholesterol (mmol/l) | LDL-C (mmol/l) | Chol:HDL-C ratio | |
| Joint British Societies (1998)4 | ≥5.0 | ≥3.0 | <5.0 | <3.0 | |||
| National Service Framework for coronary heart disease (2000)5 | <5.0 or −25% reduction | <3.0 or −30% reduction | |||||
| Joint European Societies (1998)6 | ≥5.0 | ≥3.0 | <5.0 | <3.0 | |||
| USA (NCEP-ATP III) (2001)7 | ≥2.6 (therapeutic lifestyle change) | <2.6 | |||||
| ≥3.4 (drug) | |||||||
| Canadian Recommendations (2000)8 | ≥3.5 or | >5.0 | <2.5 and | <2.0 and | <4.0 | ||